| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.07 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.11 | 0.07 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.07 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.3 | 0.07 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.054 | 0.07 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.064 | 0.07 |